Herriot Tabuteau Sells 49,666 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Posted by Brian Himes on Jul 1st, 2026

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) CEO Herriot Tabuteau sold 49,666 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $240.25, for a total value of $11,932,256.50. Following the completion of the transaction, the chief executive officer directly owned 7,229 shares in the company, valued at approximately $1,736,767.25. This trade represents a 87.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Herriot Tabuteau also recently made the following trade(s):

On Tuesday, June 9th, Herriot Tabuteau sold 49,670 shares of Axsome Therapeutics stock. The stock was sold at an average price of $241.01, for a total value of $11,970,966.70.

Axsome Therapeutics Trading Down 1.7%

AXSM traded down $4.11 during midday trading on Wednesday, reaching $240.66. 977,820 shares of the company were exchanged, compared to its average volume of 1,152,105. Axsome Therapeutics, Inc. has a one year low of $96.09 and a one year high of $260.19. The stock has a market capitalization of $12.38 billion, a P/E ratio of -64.52 and a beta of 0.60. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.32 and a current ratio of 1.39. The stock’s 50-day simple moving average is $228.50 and its 200 day simple moving average is $191.04.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last released its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.41). The company had revenue of $191.20 million for the quarter, compared to the consensus estimate of $191.10 million. Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.The company’s revenue was up 57.4% compared to the same quarter last year. As a group, analysts forecast that Axsome Therapeutics, Inc. will post -2.31 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on AXSM shares. Piper Sandler reissued an “overweight” rating and set a $258.00 target price on shares of Axsome Therapeutics in a report on Monday, May 4th. Wells Fargo & Company raised their price target on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the stock an “overweight” rating in a report on Tuesday, May 5th. UBS Group upped their price objective on shares of Axsome Therapeutics from $251.00 to $259.00 and gave the company a “buy” rating in a research note on Friday, April 10th. Morgan Stanley upgraded shares of Axsome Therapeutics from a “reduce” rating to an “overweight” rating in a research report on Thursday, June 11th. Finally, Guggenheim boosted their target price on shares of Axsome Therapeutics from $245.00 to $260.00 and gave the company a “buy” rating in a report on Monday, May 4th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $258.95.

Get Our Latest Analysis on AXSM

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD raised its position in Axsome Therapeutics by 45.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,509,870 shares of the company’s stock valued at $275,763,000 after buying an additional 472,422 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Axsome Therapeutics by 84.1% during the 3rd quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock worth $162,082,000 after acquiring an additional 609,516 shares during the last quarter. Invesco Ltd. boosted its holdings in Axsome Therapeutics by 28.6% during the 4th quarter. Invesco Ltd. now owns 1,273,494 shares of the company’s stock worth $232,591,000 after acquiring an additional 282,937 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Axsome Therapeutics by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 1,010,249 shares of the company’s stock worth $184,544,000 after acquiring an additional 12,549 shares in the last quarter. Finally, State Street Corp raised its holdings in shares of Axsome Therapeutics by 5.8% in the second quarter. State Street Corp now owns 958,503 shares of the company’s stock valued at $100,058,000 after purchasing an additional 52,483 shares during the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

(Get Free Report)

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.